Acta Oncologica and a new generation of scientists in oncology

References

• Glimelius B. 50 years with Acta Oncologica. Acta Oncol 2013;52:1–2.
   PubMed Web of Science ®Google Scholar
• Glimelius B. The 50-year anniversary of Acta Oncologica. Acta Oncol 2014;53:1–2.
   PubMed Web of Science ®Google Scholar
• Grau C, Hoyer M, Alber M, Overgaard J, Lindegaard JC, Muren LP. Biology-guided adaptive radiotherapy (BiGART) – more than a vision?Acta Oncol 2013;52:1243–7.
   PubMed Web of Science ®Google Scholar
• Therkildsen C, Bergmann TK, Henrichsen-Schnack T, Ladelund S, Nilbert M. The predictive value of KRAS, NRAS, BRAF, PIK3CA and PTEN for anti-EGFR treatment in metastatic colorectal cancer: A systematic review and meta-analysis. Acta Oncol Epub 2014 Mar 25.
   Web of Science ®Google Scholar
• Glimelius B, Cavalli Björkman N. Metastatic colorectal cancer: Current treatment and future options for improved survival. Medical approach – present status. Scand J Gastroenterol 2012;47:296–314.
   PubMed Web of Science ®Google Scholar
• Nordlinger B, Sorbye H, Glimelius B, Poston GJ, Schlag PM, Rougier P, et al. Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): A randomised controlled trial. Lancet 2008; 371:1007–16.
   PubMed Web of Science ®Google Scholar
• Saltz LB. Curative-intent treatment for colorectal liver metastases: A medical oncologist’s perspective. Am Soc Clin Oncol Educ Book 2012;32:205–8.
   Google Scholar
• Folprecht G, Cunningham D, Ross P, Glimelius B, Di Costanzo F, Wils J, et al. Efficacy of 5-fluorouracil-based chemotherapy in elderly patients with metastatic colorectal cancer: A pooled analysis of clinical trials. Ann Oncol 2004; 15:1330–8.
   PubMed Web of Science ®Google Scholar
• Padman S, Padbury R, Beeke C, Karapetis CS, Bishnoi S, Townsend AR, et al. Liver only metastatic disease in patients with metastatic colorectal cancer: Impact of surgery and chemotherapy. Acta Oncol 2013;52:1699–706.
   PubMed Web of Science ®Google Scholar
• Jones RP, Hamann S, Malik HZ, Fenwick SW, Poston GJ, Folprecht G. Defined criteria for resectability improves rates of secondary resection after systemic therapy for liver limited metastatic colorectal cancer. Eur J Cancer Epub 2014 Mar 21.
   Google Scholar
• Sunakawa Y, Ichikawa W, Takahashi T, Shimada K, Sasaki Y. Does a higher response rate to systemic chemotherapy result in a higher resection rate in patients with initially unresectable colorectal liver metastases?Acta Oncol 2013; 52:1039–40.
   PubMed Web of Science ®Google Scholar
• Schmoll HJ, Van Cutsem E, Stein A, Valentini V, Glimelius B, Haustermans K, et al. ESMO consensus guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making. Ann Oncol 2012;23:2479–516.
   PubMed Web of Science ®Google Scholar
• Folprecht G, Gruenberger T, Bechstein W, Raab HR, Weitz J, Lordick F, et al. Survival of patients with initially unresectable colorectal liver metastases treated with FOLFOX/cetuximab or FOLFIRI/cetuximab in a multidisciplinary concept (CELIM-study). Ann Oncol Epub 2014 Feb 27.
   Google Scholar
• Schwartzberg LS, Rivera F, Karthaus M, Fasola G, Canon JL, Hecht JR, et al. PEAK: A randomized, multicenter phase II study of panitumumab plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or bevacizumab plus mFOLFOX6 in patients with previously untreated, unresectable, wild-type KRAS exon 2 metastatic colorectal cancer. J Clin Oncol Epub 2014 Mar 31.
   Google Scholar
• Sorbye H, Pfeiffer P, Cavalli-Bjorkman N, Qvortrup C, Holsen MH, Wentzel-Larsen T, et al. Clinical trial enrollment, patient characteristics, and survival differences in prospectively registered metastatic colorectal cancer patients. Cancer 2009;115:4679–87.
   PubMed Web of Science ®Google Scholar
• Mol L, Koopman M, van Gils CW, Ottevanger PB, Punt CJ. Comparison of treatment outcome in metastatic colorectal cancer patients included in a clinical trial versus daily practice in The Netherlands. Acta Oncol 2013;52:950–5.
   PubMed Web of Science ®Google Scholar
• Sorbye H, Cvancarova M, Qvortrup C, Pfeiffer P, Glimelius B. Age-dependent improvement in median and long-term survival in unselected population-based Nordic registries of patients with synchronous metastatic colorectal cancer. Ann Oncol 2013;24:2354–60.
   PubMed Web of Science ®Google Scholar
• Sorbye H. Palliative chemotherapy in elderly patients with metastatic colorectal cancer: Do we know how it should be used?Acta Oncol 2012;51:819–21.
   PubMed Web of Science ®Google Scholar
• Venderbosch S, Doornebal J, Teerenstra S, Lemmens W, Punt CJ, Koopman M. Outcome of first line systemic treatment in elderly compared to younger patients with metastatic colorectal cancer: A retrospective analysis of the CAIRO and CAIRO2 studies of the Dutch Colorectal Cancer Group (DCCG). Acta Oncol 2012;51:831–9.
   PubMed Web of Science ®Google Scholar
• Papamichael D, Audisio R, Horiot JC, Glimelius B, Sastre J, Mitry E, et al. Treatment of the elderly colorectal cancer patient: SIOG expert recommendations. Ann Oncol 2009; 20:5–16.
   PubMed Web of Science ®Google Scholar
• Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004;351:337–45.
   PubMed Web of Science ®Google Scholar
• NICE. Technology appraisal guidance TA118. Bevacizumab and cetuximab for the treatment of metastatic colorectal cancer. Available from: http://guidance.nice.org.uk/TA118.2007.
   Google Scholar
• Amado RG, Wolf M, Peeters M, Van Cutsem E, Siena S, Freeman DJ, et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008;26:1626–34.
   PubMed Web of Science ®Google Scholar
• Karapetis CS, Khambata-Ford S, Jonker DJ, O’Callaghan CJ, Tu D, Tebbutt NC, et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 2008;359:1757–65.
   PubMed Web of Science ®Google Scholar
• NICE. Technology appraisal guidance TA242. Cetuximab, bevacizumab and panitumumab for the treatment of metastatic colorectal cancer after first-line chemotherapy). Available from: http://guidance.nice.org.uk/TA242.2012.
   Google Scholar
• Van Cutsem E, Kohne CH, Lang I, Folprecht G, Nowacki MP, Cascinu S, et al. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: Updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol 2011;29:2011–9.
   PubMed Web of Science ®Google Scholar
• Tveit KM, Guren T, Glimelius B, Pfeiffer P, Sorbye H, Pyrhonen S, et al. Phase III trial of cetuximab with continuous or intermittent fluorouracil, leucovorin, and oxaliplatin (Nordic FLOX) versus FLOX alone in first-line treatment of metastatic colorectal cancer: The NORDIC-VII study. J Clin Oncol 2012;30:1755–62.
   PubMed Web of Science ®Google Scholar